Analysts Set Expectations for KPTI Q1 Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – Equities researchers at Leerink Partnrs issued their Q1 2025 EPS estimates for Karyopharm Therapeutics in a research report issued to clients and investors on Wednesday, February 19th. Leerink Partnrs analyst J. Chang expects that the company will earn ($0.26) per share for the quarter. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. Leerink Partnrs also issued estimates for Karyopharm Therapeutics’ Q2 2025 earnings at ($0.25) EPS, Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS and FY2026 earnings at ($0.39) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its quarterly earnings results on Wednesday, February 19th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.02. The firm had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million.

Other equities analysts have also issued reports about the stock. StockNews.com lowered shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Karyopharm Therapeutics in a research report on Thursday. Royal Bank of Canada reaffirmed an “outperform” rating and set a $3.00 price target on shares of Karyopharm Therapeutics in a research report on Thursday. Finally, Piper Sandler raised their price target on shares of Karyopharm Therapeutics from $4.00 to $5.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $5.00.

Karyopharm Therapeutics Trading Up 1.7 %

NASDAQ KPTI opened at $0.61 on Friday. The firm has a market capitalization of $76.98 million, a P/E ratio of -0.60 and a beta of 0.06. The firm’s fifty day moving average price is $0.66 and its two-hundred day moving average price is $0.76. Karyopharm Therapeutics has a 1 year low of $0.53 and a 1 year high of $1.70.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of hedge funds have recently bought and sold shares of KPTI. Velan Capital Investment Management LP acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $27,000. Focus Partners Wealth acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $31,000. TD Waterhouse Canada Inc. acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $32,000. Two Sigma Advisers LP boosted its stake in shares of Karyopharm Therapeutics by 145.5% in the 4th quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after purchasing an additional 45,400 shares in the last quarter. Finally, Opti Capital Management LP acquired a new stake in shares of Karyopharm Therapeutics in the 4th quarter valued at approximately $85,000. 66.44% of the stock is owned by institutional investors.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).